Several experimental prostate cancer drugs have produced striking results in early-stage clinical trials, with at least one ...

Vipul R. Patel, MD, FACS, is a board-certified urologic surgeon, medical director of the Global Robotics Institute at AdventHealth, and medical director of urologic oncology at AdventHealth Cancer ...

If you or a loved one has been diagnosed with prostate cancer, you’re not alone—and you don’t have to wait long to take the next step. Whether you’re newly diagnosed, moving from active surveillance ...

In an interview, Dr. David A. Taub highlighted Prostate Cancer Awareness Month by outlining current treatment options for patients with prostate cancer. In an interview with CURE, Dr. David A. Taub ...

Prostate cancer is one of the most common cancers in the world. While many prostate cancers grow slowly and remain localized, other types are aggressive and spread quickly. That's why Dr. Carlos ...

Targeted therapies are medicines to treat cancer. They work differently than standard chemotherapy. Instead of killing all fast-growing cells or keeping them from dividing, targeted therapies work ...

ORLANDO, Fla. (Ivanhoe Newswire) - The American Cancer Society reports that about one in eight men will be diagnosed with prostate cancer in their lifetime. The average age of men who get diagnosed is ...

An estimated 1 in 8 men will be diagnosed with prostate cancer in their lifetime, often after 65. And as terrifying as that number is, a diagnosis isn’t always quite what it seems. Today, the vast ...

Johnson & Johnson (NYSE:JNJ) has entered a clinical supply agreement with GI Innovation to test a bispecific immunotherapy ...

Explore cancer drug resistance and its significant impact on treatment options and patient outcomes in modern cancer therapy.

ORLANDO, Fla. (Ivanhoe Newswire) - The American Cancer Society reports that about one in eight men will be diagnosed with prostate cancer in their lifetime. The average age of men who get diagnosed is ...

Radiation therapy (also called radiotherapy) uses high-energy beams or subatomic particles to damage the DNA inside prostate cancer cells. After enough damage, the cells cannot multiply, and they die.